Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Glycomine | 2025 | Series C | $115.0M | San Carlos |
| HepaRegeniX | 2025 | Series Unknown | $24.3M | Ulm |
| AgNext | 2025 | Series A | Undisclosed | Mohali |
| Tribune Therapeutics | 2025 | Series A | $24.7M | Stockholm |
| Supira Medical | 2025 | Series E | $120.0M | Los Gatos |
| Hillstar Bio | 2025 | Series A | $67.0M | Boston |
| Augustine Therapeutics | 2025 | Series A | $83.9M | Leuven |
| Claris Biotherapeutics | 2025 | Debt Financing | $5.6M | Jersey City |
| Newleos Therapeutics | 2025 | Series A | $93.5M | Boston |
| Aligos Therapeutics | 2025 | Post Ipo Equity | $105.0M | San Francisco |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 76 | Glycomine | Series C | $115.0M | San Carlos, United States |
| 77 | HepaRegeniX | Series Unknown | $24.3M | Ulm, Germany |
| 78 | AgNext | Series A | Undisclosed | Mohali, India |
| 79 | Tribune Therapeutics | Series A | $24.7M | Stockholm, Sweden |
| 80 | Supira Medical | Series E | $120.0M | Los Gatos, United States |
| 81 | Hillstar Bio | Series A | $67.0M | Boston, United States |
| 82 | Augustine Therapeutics | Series A | $83.9M | Leuven, Belgium |
| 83 | Claris Biotherapeutics | Debt Financing | $5.6M | Jersey City, United States |
| 84 | Newleos Therapeutics | Series A | $93.5M | Boston, United States |
| 85 | Aligos Therapeutics | Post Ipo Equity | $105.0M | San Francisco, United States |
Glycomine is an early-stage biotech working on replacement therapies for rare diseases.
HepaRegeniX is developing drugs for treating acute and chronic liver diseases.
AgNext is working at the intersection of hardware, software and analytics for quality estimation in agriculture and food.
Tribune Therapeutics specializes in building promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions.
Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.
Augustine Therapeutics is discovering and developing innovative medicines for the treatment of neuromuscular and neurodegeneratives diseases
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars.
Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Commit Biologics is a biotechnology research company developing a novel immunotherapy platform for the treatment of cancer.
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
SiteOne Therapeutics develops groundbreaking non-opioid treatments for acute, neuropathic, visceral, and musculoskeletal pain.
Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.
Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
Kivu Bioscience is a biotechnology company that focuses on developing next-generation antibody-drug conjugates to target cancer.
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
Magenta Medical is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.
Draupnir Bio is developing a new type of cholesterol-lowering medicine which prevents blood clots in the heart.
Novo Holdings has invested in 154 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novo Holdings's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 18 different industry categories.
Among tracked funding rounds, Harmony Biosciences received $248.0M in a Post Ipo Secondary round. Novo Holdings's total known invested capital is $8.5B.
Novo Holdings's average investment size is $69.9M across its portfolio of 154 companies.
Recent Novo Holdings portfolio additions include Glycomine, HepaRegeniX, AgNext, Tribune Therapeutics, Supira Medical. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors